113 related articles for article (PubMed ID: 18544445)
1. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
Surakanti SG; Agulnik M
Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
[TBL] [Abstract][Full Text] [Related]
3. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
Dodd RL; Slevin NJ
Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
[TBL] [Abstract][Full Text] [Related]
4. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
Agulnik M; Siu LL
Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):543-51. PubMed ID: 15579019
[TBL] [Abstract][Full Text] [Related]
5. Update and perspectives on non-surgical treatment of salivary gland malignancies.
Airoldi M; Cortesina G; Giordano C; Pedani F; Cavalot A; Marcato P; Beatrice F; Bumma C
Acta Otorhinolaryngol Ital; 2003 Oct; 23(5):368-76. PubMed ID: 15108487
[TBL] [Abstract][Full Text] [Related]
6. Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors.
Lalami Y; Vereecken P; Dequanter D; Lothaire P; Awada A
Curr Opin Oncol; 2006 May; 18(3):258-65. PubMed ID: 16552238
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; MandarĂ M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
[TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
10. Supporting evidence for an active treatment program for advanced salivary gland carcinomas.
Eisenberger MA
Cancer Treat Rep; 1985 Mar; 69(3):319-21. PubMed ID: 3884153
[TBL] [Abstract][Full Text] [Related]
11. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
12. How to manage an unresectable or recurrent sialoblastoma.
Saribeyoglu ET; Devecioglu O; Karakas Z; Anak S; Unuvar A; Agaoglu L; Celik A; Gulluoglu M; Bilgic B
Pediatr Blood Cancer; 2010 Aug; 55(2):374-6. PubMed ID: 20582936
[TBL] [Abstract][Full Text] [Related]
13. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Prenen H; Kimpe M; Nuyts S
Curr Opin Oncol; 2008 May; 20(3):270-4. PubMed ID: 18391625
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for esophageal cancer.
Homs MY; Voest EE; Siersema PD
Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies: aiming for the bull's-eye.
Gaguski ME
ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
[No Abstract] [Full Text] [Related]
16. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
17. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
18. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Chamberlain MC; Glantz MJ
Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
20. Exploring multi-targeting strategies for the treatment of gliomas.
Omuro AM
Curr Opin Investig Drugs; 2008 Dec; 9(12):1287-95. PubMed ID: 19037835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]